$ZYBT

Zhengye Biotechnology Holding Ltd

Zhengye Biotechnology, through its operating entity Jilin Zhengye, researches, develops, manufactures and sells veterinary vaccines, with an emphasis on livestock. Its portfolio includes vaccines for swine, cattle, goats, sheep, poultry and dogs, including monovalent, polyvalent and combined vaccines. The operating entity also has a rabies vaccine for dogs and is developing vaccines for household animals. Its products are sold under its own brand through domestic and exporting distributors. Zhengye Biotechnology makes money by manufacturing and selling veterinary vaccines in China and internationally. Its products are available in 29 provincial regions across China and are exported to Vietnam, Pakistan and Egypt. The operating entity has three veterinary vaccine production floors, 13 vaccine production lines, a quality examination center and an animal facility for vaccine development. Its principal executive offices are in Jilin Economic & Technical Development Zone, Jilin Province, China.

0
0
2

No SEC Form 4 filings for $ZYBT in the last 30 days.

See all $ZYBT insider activity →

Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026

Zhengye Biotechnology (ZYBT) reported its H1 2026 financial results, showing a net revenue decline of 18.3% to RMB50.9 million (US$7.5 million) and a gross profit decrease of 13.8% to RMB16.7 million (US$2.5 million). Despite these declines, the company improved its gross profit margin by 1.8 percentage points to 32.9%. Operating expenses decreased by 22.2% to RMB37.6 million, and the net loss narrowed by 13.3% to RMB22.2 million (US$3.3 million).

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.83%

U.S. stocks closed higher on Friday, with the Dow Jones up 0.83%, S&P 500 up 0.59%, and Nasdaq up 0.64%. Top performers included Amazon, Cisco, and Visa, while Verizon, 3M, and Home Depot declined. Moderna and Crown Castle also saw significant gains. Oil prices fell slightly, and gold futures rose. The CBOE Volatility Index decreased by 3.70%.

ZYBT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ZYBT (Zhengye Biotechnology Holding Ltd). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.

Recent ZYBT coverage spans earnings, market movers and financial news.

What's driving ZYBT

AlphAI scores every news story that mentions ZYBT with an AI model for sentiment and relevance, and aggregates insider trades from Zhengye Biotechnology Holding Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ZYBT

Score
$ZYBTMedEarnings

Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026

Zhengye Biotechnology (ZYBT) reported its H1 2026 financial results, showing a net revenue decline of 18.3% to RMB50.9 million (US$7.5 million) and a gross profit decrease of 13.8% to RMB16.7 million (US$2.5 million). Despite these declines, the company improved its gross profit margin by 1.8 percentage points to 32.9%. Operating expenses decreased by 22.2% to RMB37.6 million, and the net loss narrowed by 13.3% to RMB22.2 million (US$3.3 million).

Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement

Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) said Nasdaq notified it on Aug. 5, 2026 that it regained compliance with the $1.00 minimum bid price requirement under Nasdaq Rule 5550(a)(2). Nasdaq previously flagged ZYBT for trading below $1.00 for 30 straight business days, but determined the bid was at or above $1.00 for the last 10 consecutive sessions from July 20 to Aug. 4.

Top Biotech Gainers: ZYBT Skyrockets, ADVB Drops Planned Offering, STIM Gets New CFO, RDGT On Watch

Biotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).

Related tickers